Therapeutic antibodies directed at G protein-coupled receptors.
G protein-coupled receptors (GPCRs) are one of the most important classes of targets for small molecule drug discovery, but many current GPCRs of interest are proving intractable to small molecule discovery and may be better approached with bio-therapeutics. GPCRs are implicated in a wide variety of diseases where antibody therapeutics are currently used. These include inflammatory diseases such as rheumatoid arthritis and Crohn disease, as well as metabolic disease and cancer. Raising antibodies to GPCRs has been difficult due to problems in obtaining suitable antigen because GPCRs are often expressed at low levels in cells and are very unstable when purified. A number of new developments in over-expressing receptors, as well as formulating stable pure protein, are contributing to the growing interest in targeting GPCRs with antibodies. This review discusses the opportunities for targeting GPCRs with antibodies using these approaches and describes the therapeutic antibodies that are currently in clinical development.
Hutchings
Catherine J
CJ
Heptares Therapeutics, Biopark, Welwyn Garden City, Hertfordshire, UK.
Koglin
Markus
M
Marshall
Fiona H
FH
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D055808:Drug Discovery; D006801:Humans; D043562:Receptors, G-Protein-Coupled / Q000276:immunology
D000906:Antibodies; D043562:Receptors, G-Protein-Coupled